Showing 1621-1630 of 5771 results for "".
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-american-academy-of-ophthalmology-annual-meeting/2481136/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30-October 3, 2022 in Chicago. Key Glaucoma Presentations: Bryan CH Ang, MD Novel
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-trial-of-eyp-1901-for-the-treatment-of-non-proliferative-diabetic-retinopathy/2481131/EyePoint Pharmaceuticals announced that the first patient has been dosed in the phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting non-proliferative diabetic retinopathy (NPDR).
- TearSolutions Announces Results From First-In-Human Clinical Trial Published in Corneahttps://modernod.com/news/tearsolutions-announces-results-from-first-in-human-clinical-trial-published-in-cornea/2481129/TearSolutions announced that the
- Neurophth Announces First Patient Dosed in Phase 3 Clinical Trial for the Gene Therapy Treatment of LHONhttps://modernod.com/news/neurophth-announces-first-patient-dosed-in-phase-3-clinical-trial-for-the-gene-therapy-treatment-of-lhon/2481126/Neurophth Therapeutics announced that the first patient has been dosed in phase 3 clinical trial for the treatment of Leber hereditary optic neuropathy (LHON). Neurophth is conducting a phase 1/2/3, multicenter, two-part study aimed at evaluating the safety, tolerability, and effic
- Harrow Announces FDA Approval of Iheezo for Ocular Surface Anesthesiahttps://modernod.com/news/harrow-announces-fda-approval-of-iheezo-for-ocular-surface-anesthesia/2481122/Harrow and Sintetica SA jointly announced the FDA approval of Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. Iheezo is a sterile, single-patient‑use, physician‑administered, ophthalmic gel preparation, containing no preservatives, that i
- Samsung Bioepis Presents Data from its Ophthalmology Biosimilar Portfolio at AAO 2022 Annual Meetinghttps://modernod.com/news/samsung-bioepis-presents-data-from-its-ophthalmology-biosimilar-portfolio-at-aao-2022-annual-meeting/2481121/Samsung Bioepis announced that three scientific abstracts relating to its ophthalmology biosimilar portfolio will be presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held from September 30 to October 3, 2022 in Chicago. The phase 3 study on SB15, a
- Ocular Therapeutix Announces Interim 7-month Data from US Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-7-month-data-from-us-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2481120/Ocular Therapeutix announced interim 7-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The data will b
- Outlook Therapeutics and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-and-amerisourcebergen-announce-strategic-commercialization-agreement-for-ons-5010-for-the-treatment-of-wet-amd/2481116/Outlook Therapeutics and AmerisourceBergen, a specialty pharmaceutical distribution company, announced that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010/Lytenava (bevacizumab-vikg), if app
- Bausch + Lomb to Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meetinghttps://modernod.com/news/bausch-lomb-to-present-new-scientific-data-and-analyses-during-the-american-academy-of-ophthalmology-annual-meeting/2481113/Bausch + Lomb announced that seven scientific podium and poster presentations involving its products and pipeline, as well as data from the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the American Academ
- Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Networkhttps://modernod.com/news/alimera-announces-agreement-with-jaeb-center-for-health-research-on-behalf-of-the-drcr-retina-network/2481112/Alimera Sciences announced that it has entered into an agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), acting on the behalf of the DRCR Retina Network, to support and provide Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release